No Data
Sinuo Medicine-B (02257.HK): Lu Yang and Sheng Muxian resign as members of the investigation committee.
Grainews October 29th 丨 Sanofi-B (02257.HK) announced that the board of directors has established an investigation committee, composed of the board chairman and executive director Lu Yang, and all independent non-executive directors, namely Chang Hai, Huang Mengying and Sheng Muxian, to investigate the incident, namely potential default by the issuer of the private placement bonds invested by the fund, expecting a significant adverse change in the net asset value of the fund. The board of directors has received voluntary resignation notices from Lu Yang and Sheng Muxian as members of the investigation committee, in order to allocate more time to their respective duties prior to being appointed as members of the investigation committee, effective October 29, 2024.
Express News | National Medical Products Administration: Deploys pilot work on segmented production reform of biological products.
Sudden Movement Spotlight | Biomedical Class B shares rose in the afternoon, LKYG-B up 30%, institutions bullish on sector further recovery space
Biomedical Class B shares rose in the afternoon, as of the time of publication, Lai Kai Medicine-B rose by 27.88%, to 7.89 Hong Kong dollars; YimingAngke-B rose by 17.91%, to 5.86 Hong Kong dollars; Yasheng Medicine-B rose by 5.74%, to 46.95 Hong Kong dollars.
San Nuo Medicine-B (02257): Pan Honghui appointed as an executive director.
San Nova Pharmaceuticals-B (02257) announced that Dr. Pan Honghui has been appointed as an executive director, effective from October 2024...
San Nuoyi Medicine-B (02257.HK) received Pan Honghui's off-exchange shareholding of 17.5277 million ordinary shares, worth approximately 58.8931 million Hong Kong dollars
Reported on October 8th, according to the documents disclosed by the Hong Kong Stock Exchange on October 8th, Pan Honghui increased his shareholding off-market on October 2nd at an average price of HK$3.36 per share, acquiring 17.5277 million ordinary shares of Sanofi-Aventis-B (02257.HK) worth approximately HK$58.8931 million. After the increase, Pan Honghui's latest shareholding is 17.5277 million shares, with a warehouse ratio rising from 0.00% to 20.00%. Additional information: On October 2, 2024, pursuant to the Subscription
Sirnaomics Has Been Subscribed for 17,527,696 Subscription Shares, New Capital Injection to Promote Business Growth and Development
No Data
No Data